Vaxart Inc (NAS:VXRT)
$ 0.7303 0.0538 (7.95%) Market Cap: 129.57 Mil Enterprise Value: 102.71 Mil PE Ratio: 0 PB Ratio: 2.28 GF Score: 51/100

Vaxart Inc at H C Wainwright Global Investment Conference (Virtual) Transcript

Sep 12, 2022 / 11:00AM GMT
Release Date Price: $2.89 (+0.70%)
Emily Bodnar
H.C. Wainwright - Analyst

Hello, everyone, and thank you for joining the H.C. Wainwright 24th Annual Global Investment hybrid conference on September 12 to 14. My name is Emily Bodnar, and I'm an equity research analyst at H.C. Wainwright. While we are hybrid this year, we are confident we are going to be able to provide value to you with over 550 companies presenting at this conference.

Please join us for one-on-one meetings, corporate presentations, and panels that will be available live and streaming on September 12 to 14. With that said, I'd like to introduce Andrei Floroiu, Chief Executive Officer; James Cummings, Chief Medical Officer; and Sean Tucker, Founder and Chief Scientific Officer of Vaxart, which focuses on developing oral vaccines for viruses.

Andrei Floroiu
Vaxart, Inc. - President & CEO

Thank you, Emily. We're very excited to be presenting today, particularly in light of our recent Phase II COVID data that my colleagues are going to cover in more detail. We're excited to talk to you today because we believe that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot